Pharmacotherapy, pharmacogenetics and pharmaceutical technology
PRINCIPAL INVESTIGATORS
- Pedro Alía Ramos
- Helena Colom Codina
- Josep Manel Llop Talaveron
- Beatriz Candás Estébanez
- Elisabet Leiva Badosa
CLINICAL RESEARCHERS
- Maria Bella Badia Tahull
- Josep Maria Suñe Negre
- Núria Llecha Cano
- Montserrat Miñarro Carmona
- Roser Juvany Roig
- Josep Ramon Tico Grau
- Ariadna Padró Miquel
- Maria Pilar Pérez Lozano
- Encarna Garcia Montoya
- Ariadna Padullés Zamora
- Eugènia Santacana Juncosa
- Marc Suñé Pou
- Khadija Rouaz El Hajoui
PREDOCTORAL RESEARCHERS
- Montserrat Colls Gonzalez
- Leticia Garrido Sanchez
- Javier Martínez Casanova
- Sara Cobo Sacristán
- Lorena Santulario Verdú
- Ana Suarez-Lledo Grande
SCIENTIFIC SUPPORT
- Sara Quiles Petidier
MANAGEMENT SUPPORT
- Ana Maria Ferrer Artola
- Laura Canals Vilaseca
Translational Medicine
Digestive system, diagnostics, pharmacogenetics, care support and clinical prevention
Scientific production
39
PAPERS
Average IF: 4,10
26
LED PAPERS
Average IF: 4,68
5 PUBLICATIONS IN FIRST DECILE
25 PUBLICATIONS IN FIRST QUARTILE
33 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Garrido Sanchez,L;Leiva Badosa,E;Llop Talaveron,J;Pintó Sala,X;Lozano Andreu,T;Corbella Inglés,E;Alia Ramos,P et al, Blood Phytosterol Concentration and Genetic Variant Associations in a Sample Population, Nutrients, 2024;16(7):doi:10.3390/nu16071067
- Mallén,A;Narváez,DA;Pujol,MD;Navarro,E;Suñé Negre,JM;García Montoya,E;Pérez Lozano,P et al, Development of cationic solid lipid nanoparticles incorporating cholesteryl-9-carboxynonanoate (9CCN) for delivery of antagomiRs to macrophages, Eur J Pharm Biopharm, 2024;197114238-114238, doi:10.1016/j.ejpb.2024.114238
- Giménez Pérez,M;Hernández,S;Padullés,A;Boix Palop,L;Grau,S;Badia,JM;Ferrer,R et al, Impact of an antimicrobial stewardship program indicator on the appropriateness of the empiric antibiotic treatment of urinary source Escherichia coli bacteraemia, Int. J. Antimicrob. Agents, 2024;64(2):doi:10.1016/j.ijantimicag.2024.107202
- Esteve Garcia,A;Cobos,E;Sau,C;Padró Miquel,A;Catalá Mora,J;Barberán Martínez,P;Millán,JM et al, Deciphering complexity: TULP1 variants linked to an atypical retinal dystrophy phenotype, Front Genet, 2024;151352063-1352063, doi:10.3389/fgene.2024.1352063
- Alsoud,D;Moes,D;Wang,ZG;Soenen,R;Layegh,Z;Barclay,M;Mizuno,T et al, Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Ther Drug Monit, 2024;46(3):291-308, doi:10.1097/FTD.0000000000001204
Research highlights
PROJECTS
1 Granted competitive project
4 Ongoing competitive projects
5 Started clinical trials
12 Ongoing clinical trials
PUBLISHED WORKS
2 Clinical guidelines
4 Theses
NETWORKS
AGAUR SGR
ENOTTA
CIBERINFEC
Selected projects
- PR213/19. Antibiotic pharmacokinetic/pharmacodynamic target attaintment during continuous renal replacement therapy with a high absorptive membrane (oXiris®). BAXTER HEALTHCARE CORPORATION. Budget: 9.760,37€. 2024-2025. PI: Colom Codina, Helena.
- 202040-32. Catalan interhospital network of genetic variants to improve genetic diagnosis in rare diaseases. Fundació La Marató de TV3. Budget: 26.625€. 2021-2024. PI: PADRÓ MIQUEL, ARIADNA.
- 2024-159-1. ‘Impacto clínico y económico de la individualización posológica de infliximab guiada por modelos (MIPD) en el tratamiento de la enfermedad inflamatoria intestinal’. 2024- . PI: Núria Padullés Zamora.
- 2023-330-1. LONG-TERM EFFECTSS OF A STEPWISE, MULTIMODAL, NON-RESTRICTIVE ANTIMICROBIAL STEWARDSHIP PROGRAMME TO REDUCE BROAD-SPECTRUM ANTIBIOTIC CONSUMPTION IN THE ICU. 2023- . PI: Ariadna Padullés Zamora.
- FEF-TGI-2024. FARMACOVIGILANCIA DE TERAPIA GÉNICA IN VIVO EN ESPAÑA: ONASEMNOGÉN ABEPARVOVEC Y VORETIGÉN NEPARVOVEC. Fundación Española de Farmacia Hospitalaria. 2024- . PI: LETICIA GARRIDO SANCHEZ.